
Remepy is pioneering hybrid drugs, which are a new class of pharmaceutical assets that combine traditional drugs with proprietary software-based digital interventions. These "digital molecules" are therapeutic mobile apps designed to trigger physiological effects through the brain, thereby enhancing the effectiveness of conventional drugs. The company's approach redefines combination therapy by integrating software with drugs to create SaMD (Software as a Medical Device) drug combinations, enabling personalized treatment at scale. Remepy focuses on diseases where changes in brain connectivity, immune system modulation, and behavioral adjustments are synergistic with drug effects, with current areas of interest including Parkinson's Disease, Oncology, and Women's Health. They leverage AI-driven digital treatment protocols that adapt based on patient feedback, activity, and progress to optimize drug performance and address symptoms.

Remepy is pioneering hybrid drugs, which are a new class of pharmaceutical assets that combine traditional drugs with proprietary software-based digital interventions. These "digital molecules" are therapeutic mobile apps designed to trigger physiological effects through the brain, thereby enhancing the effectiveness of conventional drugs. The company's approach redefines combination therapy by integrating software with drugs to create SaMD (Software as a Medical Device) drug combinations, enabling personalized treatment at scale. Remepy focuses on diseases where changes in brain connectivity, immune system modulation, and behavioral adjustments are synergistic with drug effects, with current areas of interest including Parkinson's Disease, Oncology, and Women's Health. They leverage AI-driven digital treatment protocols that adapt based on patient feedback, activity, and progress to optimize drug performance and address symptoms.
Company Overview
Remepy is a digital health company specializing in the development of hybrid drugs – a product that includes a traditional pharmacological component and a digital therapeutic app. Remepy’s digital therapeutics applications are developed as Software as a Medical Device (SaMD), in accordance with applicable medical device regulations of the US Food and Drug Administration (FDA) and the International Organization of Standards (ISO). The company is headquartered in the US with R&D operations in Ramat Gan, Israel. As the legal manufacturer, Remepy is responsible for management oversight, regulatory affairs, quality system compliance, document control, design and development, procurement, marketing and sales, complaint handling, manufacturing, and distribution or deployment of its products.
Role Description
The Director of Business Development will be a hands-on, execution-driven leader responsible for building and closing strategic partnerships with pharmaceutical companies. This role owns the end-to-end business development process, from opportunity identification through signed agreements - and works closely with Remepy’s leadership, clinical, regulatory, and product teams to translate our Hybrid Drugs™ platform into commercial partnerships.
Preferred location: Boston or New York. Flexibility to travel required
What you’ll do
What we’re looking for